Retail sale of other food
MYCOTECH PHARMA AS
Revenue 2024
NOK 3.5m
Operating profit
NOK −29.6m
Equity
NOK 20.2m
Incorporated
2022
Share capital
NOK 11.3m
Roles
Revisor
Styrets lederKnut Christian Espeseth
StyremedlemFrode Marc Bohan
Auditor
Auditor at related companies
None of the 3 related companies use the same auditor.
| Company | Auditor | |
|---|---|---|
| IMMUNOPHARMA AS | FORVIS MAZARS AS | different |
| IP EQOLOGY HOLDCO AS | FORVIS MAZARS AS | different |
| SMARTFISH SPORTS NUTRITION AS | FORVIS MAZARS AS | different |
Shareholders
| Name | Stake | Shares | Year |
|---|---|---|---|
| IMMUNOPHARMA AS | 97.8% | 110330000.000000 | 2025 |
| NICOLINE INVEST AS | 0.7% | 770000.000000 | 2025 |
| BOHAN & CO AS | 0.7% | 770000.000000 | 2025 |
| PVO INVEST AS | 0.2% | 256410.000000 | 2025 |
| JAN FR. BJERKENES HOLDING AS | 0.1% | 165000.000000 | 2025 |
| CINCO INVEST AS | 0.1% | 165000.000000 | 2025 |
| ROGER MORTEN MORTENSEN | 0.1% | 128205.000000 | 2025 |
| STEIN OLE VRENNE | 0.1% | 110000.000000 | 2025 |
| CARL AF PETERSENS | 0.1% | 64105.000000 | 2025 |
| LANDMARK INVEST AS | 0.0% | 55000.000000 | 2025 |
| 3LP NORGE AS | 0.0% | 27500.000000 | 2025 |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.